ArticleScientific reports2026
Mouse model of X-linked Alport syndrome with K229X mutation in the COL4A5 gene.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
X-linked Alport syndrome (XLAS) is a hereditary glomerular basement membrane (GBM) disease caused by COL4A5 mutations, leading to end-stage renal disease. With unclear pathogenesis and limited treatments, reliable animal models are urgently needed. In this study, the mutation K229X in COL4A5 detected in XLAS patients was introduced into mice model by CRISPR/Cas. The clinical manifestations and pathological changes in the K229X mice were characterized through urinary and serum tests, histopathology, immunofluorescence, and transmission electron microscopy. In K229X male mice, we observed significant hematuria and proteinuria, along with azotemia, and noted a marked decrease in the expression of COL4A5 at both the mRNA and protein levels within the kidneys. Pathological examination revealed glomerulosclerosis, increased mononuclear cells in the renal interstitium, interstitial fibrosis, and absence of α5 collagen IV, with histological abnormalities in the glomeruli, renal tubules, and interstitium progressing with age. Electron microscopy found irregular thickening of the GBM, accompanied by irregular layering. The phenotypic and pathological features of this mouse model are consistent with those observed in XLAS patients and other previously established mouse models. This K229X mouse model is of significant importance for exploring the pathogenic mechanisms of XLAS and researching potential therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.